We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
Read MoreHide Full Article
Key Takeaways
Repligen will acquire BioLife Solutions for about $1.5 billion to expand its cell therapy portfolio.
RGEN expects the deal to boost revenues, margins and adjusted EPS, with planned cost synergies after closing.
RGEN expects preliminary Q2 2026 revenue growth of about 12% (reported) and 13% (organic) year over year.
Repligen Corporation (RGEN - Free Report) announced that it has entered into a definitive agreement to acquire Washington-based BioLife Solutions (BLFS - Free Report) , a leading developer of bioproduction products and services, for a total value of approximately $1.5 billion, combining cash and stock.
Shares of Repligen were up 2.3%, while BioLife stock was up 6.7% yesterday, following the announcement.
The impending acquisition is expected to strengthen Repligen's position in the fast-growing cell therapy market by adding BioLife's market-leading biopreservation media platform and other cell processing tools.
The deal appears to be a strong strategic fit for Repligen as it is expected to complement the company's existing solutions for cell therapy customers while adding a high-margin consumables business with attractive recurring revenues. The cell therapy market is among the fastest-growing areas of biotechnology, with commercial revenues projected to grow more than 20% annually through the end of the decade.
The transaction is expected to be closed in the fourth quarter of 2026, subject to customary closing conditions.
RGEN’s Price Performance
Year to date, shares of Repligen have lost 14.5% against the industry’s increase of 3%.
Image Source: Zacks Investment Research
More on RGEN’s Latest Acquisition
Per the latest agreement, BioLife shareholders will receive $11.25 in cash plus 0.1442 shares of Repligen stock for each BioLife share they own, equivalent to $31 per share. The acquisition will add BioLife's market-leading biopreservation media portfolio used in 18 commercially approved cell therapies to Repligen’s commercial portfolio.
Repligen expects the deal to be accretive to revenue growth, adjusted margins and adjusted earnings per share (EPS), by at least 5 cents in the first year following closing and at least 25 cents in the second year. The company also expects at least $20 million in first-year cost synergies and $30 million in the second year by eliminating certain costs and optimizing business operations.
Repligen plans to fund the cash portion of the acquisition using its existing cash reserves.
RGEN & BLFS Preliminary Q2 2026 Results
Along with the acquisition announcement, Repligen reported preliminary second-quarter 2026 results, expecting preliminary revenue growth of around 12% on a reported basis and 13% on an organic basis year over year. The company is scheduled to report second-quarter results on July 28, 2026, before the opening bell.
BioLife also reported preliminary results for the second quarter of 2026. The company expects preliminary second-quarter revenues of $28.5 million, reflecting an increase of 21% year over year. The company plans to report second-quarter 2026 results on Aug. 6, 2026.
Over the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2026 earnings per share have risen from $1.24 to $1.25, while estimates for 2027 have increased from $1.70 to $1.76 during the same time. KNSA shares have soared 51.3% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 1.53%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $4.92 during the same time. LQDA shares have surged 152.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
Key Takeaways
Repligen Corporation (RGEN - Free Report) announced that it has entered into a definitive agreement to acquire Washington-based BioLife Solutions (BLFS - Free Report) , a leading developer of bioproduction products and services, for a total value of approximately $1.5 billion, combining cash and stock.
Shares of Repligen were up 2.3%, while BioLife stock was up 6.7% yesterday, following the announcement.
The impending acquisition is expected to strengthen Repligen's position in the fast-growing cell therapy market by adding BioLife's market-leading biopreservation media platform and other cell processing tools.
The deal appears to be a strong strategic fit for Repligen as it is expected to complement the company's existing solutions for cell therapy customers while adding a high-margin consumables business with attractive recurring revenues. The cell therapy market is among the fastest-growing areas of biotechnology, with commercial revenues projected to grow more than 20% annually through the end of the decade.
The transaction is expected to be closed in the fourth quarter of 2026, subject to customary closing conditions.
RGEN’s Price Performance
Year to date, shares of Repligen have lost 14.5% against the industry’s increase of 3%.
Image Source: Zacks Investment Research
More on RGEN’s Latest Acquisition
Per the latest agreement, BioLife shareholders will receive $11.25 in cash plus 0.1442 shares of Repligen stock for each BioLife share they own, equivalent to $31 per share. The acquisition will add BioLife's market-leading biopreservation media portfolio used in 18 commercially approved cell therapies to Repligen’s commercial portfolio.
Repligen expects the deal to be accretive to revenue growth, adjusted margins and adjusted earnings per share (EPS), by at least 5 cents in the first year following closing and at least 25 cents in the second year. The company also expects at least $20 million in first-year cost synergies and $30 million in the second year by eliminating certain costs and optimizing business operations.
Repligen plans to fund the cash portion of the acquisition using its existing cash reserves.
RGEN & BLFS Preliminary Q2 2026 Results
Along with the acquisition announcement, Repligen reported preliminary second-quarter 2026 results, expecting preliminary revenue growth of around 12% on a reported basis and 13% on an organic basis year over year. The company is scheduled to report second-quarter results on July 28, 2026, before the opening bell.
BioLife also reported preliminary results for the second quarter of 2026. The company expects preliminary second-quarter revenues of $28.5 million, reflecting an increase of 21% year over year. The company plans to report second-quarter 2026 results on Aug. 6, 2026.
Repligen Corporation Price
Repligen Corporation price | Repligen Corporation Quote
RGEN's Zacks Rank & Stocks to Consider
Repligen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Kiniksa Pharmaceuticals (KNSA - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2026 earnings per share have risen from $1.24 to $1.25, while estimates for 2027 have increased from $1.70 to $1.76 during the same time. KNSA shares have soared 51.3% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 1.53%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $4.92 during the same time. LQDA shares have surged 152.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.